IBDEI1RQ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,30057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30057,1,3,0)
 ;;=3^Coagulation Defects,Unspec
 ;;^UTILITY(U,$J,358.3,30057,1,4,0)
 ;;=4^D68.9
 ;;^UTILITY(U,$J,358.3,30057,2)
 ;;=^5002364
 ;;^UTILITY(U,$J,358.3,30058,0)
 ;;=D69.1^^118^1496^22
 ;;^UTILITY(U,$J,358.3,30058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30058,1,3,0)
 ;;=3^Qualitative platelet defects
 ;;^UTILITY(U,$J,358.3,30058,1,4,0)
 ;;=4^D69.1
 ;;^UTILITY(U,$J,358.3,30058,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,30059,0)
 ;;=D47.3^^118^1496^8
 ;;^UTILITY(U,$J,358.3,30059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30059,1,3,0)
 ;;=3^Essential (hemorrhagic) thrombocythemia
 ;;^UTILITY(U,$J,358.3,30059,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,30059,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,30060,0)
 ;;=D69.0^^118^1496^3
 ;;^UTILITY(U,$J,358.3,30060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30060,1,3,0)
 ;;=3^Allergic purpura
 ;;^UTILITY(U,$J,358.3,30060,1,4,0)
 ;;=4^D69.0
 ;;^UTILITY(U,$J,358.3,30060,2)
 ;;=^5002365
 ;;^UTILITY(U,$J,358.3,30061,0)
 ;;=D69.2^^118^1496^19
 ;;^UTILITY(U,$J,358.3,30061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30061,1,3,0)
 ;;=3^Nonthrombocytopenic purpura NEC
 ;;^UTILITY(U,$J,358.3,30061,1,4,0)
 ;;=4^D69.2
 ;;^UTILITY(U,$J,358.3,30061,2)
 ;;=^5002366
 ;;^UTILITY(U,$J,358.3,30062,0)
 ;;=D69.3^^118^1496^18
 ;;^UTILITY(U,$J,358.3,30062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30062,1,3,0)
 ;;=3^Immune thrombocytopenic purpura
 ;;^UTILITY(U,$J,358.3,30062,1,4,0)
 ;;=4^D69.3
 ;;^UTILITY(U,$J,358.3,30062,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,30063,0)
 ;;=D69.41^^118^1496^9
 ;;^UTILITY(U,$J,358.3,30063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30063,1,3,0)
 ;;=3^Evans syndrome
 ;;^UTILITY(U,$J,358.3,30063,1,4,0)
 ;;=4^D69.41
 ;;^UTILITY(U,$J,358.3,30063,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,30064,0)
 ;;=D69.51^^118^1496^21
 ;;^UTILITY(U,$J,358.3,30064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30064,1,3,0)
 ;;=3^Posttransfusion purpura
 ;;^UTILITY(U,$J,358.3,30064,1,4,0)
 ;;=4^D69.51
 ;;^UTILITY(U,$J,358.3,30064,2)
 ;;=^5002368
 ;;^UTILITY(U,$J,358.3,30065,0)
 ;;=D69.59^^118^1496^23
 ;;^UTILITY(U,$J,358.3,30065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30065,1,3,0)
 ;;=3^Secondary thrombocytopenia NEC
 ;;^UTILITY(U,$J,358.3,30065,1,4,0)
 ;;=4^D69.59
 ;;^UTILITY(U,$J,358.3,30065,2)
 ;;=^5002369
 ;;^UTILITY(U,$J,358.3,30066,0)
 ;;=D69.8^^118^1496^10
 ;;^UTILITY(U,$J,358.3,30066,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30066,1,3,0)
 ;;=3^Hemorrhagic Conditions NEC
 ;;^UTILITY(U,$J,358.3,30066,1,4,0)
 ;;=4^D69.8
 ;;^UTILITY(U,$J,358.3,30066,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,30067,0)
 ;;=D69.6^^118^1496^24
 ;;^UTILITY(U,$J,358.3,30067,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30067,1,3,0)
 ;;=3^Thrombocytopenia, unspecified
 ;;^UTILITY(U,$J,358.3,30067,1,4,0)
 ;;=4^D69.6
 ;;^UTILITY(U,$J,358.3,30067,2)
 ;;=^5002370
 ;;^UTILITY(U,$J,358.3,30068,0)
 ;;=M31.1^^118^1496^25
 ;;^UTILITY(U,$J,358.3,30068,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30068,1,3,0)
 ;;=3^Thrombotic microangiopathy
 ;;^UTILITY(U,$J,358.3,30068,1,4,0)
 ;;=4^M31.1
 ;;^UTILITY(U,$J,358.3,30068,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,30069,0)
 ;;=D69.9^^118^1496^11
 ;;^UTILITY(U,$J,358.3,30069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30069,1,3,0)
 ;;=3^Hemorrhagic condition, unspecified
 ;;^UTILITY(U,$J,358.3,30069,1,4,0)
 ;;=4^D69.9
 ;;^UTILITY(U,$J,358.3,30069,2)
 ;;=^5002371
 ;;^UTILITY(U,$J,358.3,30070,0)
 ;;=I80.9^^118^1496^20
 ;;^UTILITY(U,$J,358.3,30070,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,30070,1,3,0)
 ;;=3^Phlebitis and thrombophlebitis of unspecified site
